Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Thomas

Physician Assistant, Medical North Little Rock, AR Physician Assistant

NPI 1013281609 CMS profile 10413390

4200 Stockton Dr, North Little Rock, AR 72117

Open in the dashboard

General payments

$5,888

231 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Thomas of North Little Rock, AR is reported in the CMS Open Payments database as having received $5,888 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $835 49
2024 General $455 22
2023 General $997 41
2022 General $1,637 70
2021 General $1,964 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Thomas
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jeffrey Thomas were reported at $835. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jeffrey Thomas Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,964 $156 $41–$563 $132
2022 $1,637 $185 $55–$649 $149
2023 $997 $199 $58–$717 $160
2024 $455 $206 $62–$740 $164
2025 $835 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Endo Pharmaceuticals Inc. $1,258 4 payments
  2. Sumitomo Pharma America, Inc. $612 36 payments
  3. Janssen Biotech, Inc. $554 31 payments
  4. Astellas Pharma US Inc $538 18 payments
  5. Dendreon Pharmaceuticals LLC $457 19 payments
  6. Novartis Pharmaceuticals Corporation $456 23 payments
  7. Myriad Genetic Laboratories, Inc. $376 12 payments
  8. AbbVie, Inc. $232 13 payments
  9. Blue Earth Diagnostics Limited $220 12 payments
  10. Myovant Sciences Inc. $167 10 payments
  11. Other $1,019 53 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,384 227 payments
  2. Consulting Fee $1,215 1 payment
  3. Education $289 3 payments
Products named General payments · program years 2021–2025
  1. XIAFLEX $1,258 4 payments
  2. ERLEADA $463 25 payments
  3. PROVENGE $457 19 payments
  4. PLUVICTO $456 23 payments
  5. ORGOVYX Hormone Therapy $406 18 payments
  6. XTANDI $300 16 payments
  7. GEMTESA $289 24 payments
  8. myRisk $194 5 payments
  9. ORGOVYX Prostate Cancer $161 8 payments
  10. PROLARIS $158 5 payments
  11. Other $1,922 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,754

Median for Physician Assistant: 241

Drug cost

$379,077

Median for Physician Assistant: $4,110

Branded share of claims

17.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 21 $286,989
Myrbetriq Mirabegron Brand 49 $33,064
Gemtesa Vibegron Brand 36 $25,413
Tamsulosin Hcl Generic 590 $9,646
Solifenacin Succinate Generic 128 $4,767
Finasteride Generic 287 $3,386
Silodosin Generic 49 $2,926
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 26 $2,833
Testosterone Cypionate Generic 47 $2,041
Dutasteride Generic 54 $1,582

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$341,913

Of which drugs: $181,731

Medicare patients

784

Average age 75

Services billed

13,635

74 women, 710 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 49%
Arthritis 45%
Ischemic heart disease 42%
Diabetes 33%
Chronic kidney disease 24%
Atrial fibrillation 23%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 45 5,280 $109,347
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 44 169 $21,145
Injection, degarelix, 1 mg J9155 Office 17 2,640 $6,663

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PLUVICTO
  • Novartis Pharmaceuticals Corporation $160
$160 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $47
$47 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $39
$39 — —
IQIRVO
  • Ipsen Biopharmaceuticals, Inc $23
$23 — —
Cysview
  • Photocure Inc $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record